Todd Chappell, senior vice president of strategy and portfolio planning at Korro Bio, brings twenty years of product development and product strategy experience.
Todd is a veteran industry executive who has led several early-stage therapeutic programs from discovery stage through to clinical trials. Most recently, he served as CEO for two seed-staged companies, Rasio Therapeutics, Inc. and Perceptive Navigation, LLC. Prior to being CEO, Mr. Chappell managed a portfolio of start-up pharmaceutical and medical device companies as an entrepreneur-in-residence at a private-public partnership involving Johns Hopkins University, National Institutes of Health, Medimmune, NEA, and SROne. From 2009 to 2012, Todd ran Shape Pharmaceuticals, Inc., a portfolio company of HealthCare Ventures, LLC, where he oversaw all day-to-day operations for the development of a novel HDAC inhibitor for Cutaneous-T-Cell-Lymphoma. Prior to Shape, Mr. Chappell was at CombinatoRx, Inc. for eight years and served as Executive Director of New Products. In that role, Mr. Chappell led the advancement of three programs from assay stage into human clinical studies.
Todd holds a B.S. from University of California at Los Angeles and a M.B.A. from Boston University.